Related Experiment Video
Updated: Mar 19, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Rationale and design of the Chinese Atrial Fibrillation Registry Study
Xin Du1, Changsheng Ma2, Jiahui Wu1
1Beijing Anzhen Hospital, Capital Medical University, No 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.
Insights
The Chinese Atrial Fibrillation Registry (CAFR) study is evaluating current atrial fibrillation (AF) management in China. This large-scale registry will provide real-world data on AF patient outcomes and treatment uptake.
Area of Science:
- Cardiology
- Epidemiology
- Clinical Research
Background:
- Limited robust data exists on contemporary atrial fibrillation (AF) management in China.
- Recent years have seen dramatic changes in AF treatment practices.
- Understanding current practices in a large Chinese AF population is crucial.
Purpose of the Study:
- To evaluate the uptake and outcomes of different therapies in a large Chinese AF population.
- To provide insights into 'real world' clinical epidemiology of AF management.
- To establish one of the largest registries of Asian AF patients.
Main Methods:
- The Chinese Atrial Fibrillation Registry (CAFR) study aims to enroll 20,000 AF patients.
- Data collection includes demographics, medical history, treatments, and outcomes over 6-month follow-ups until 2020.
- Blood samples will be stored for future biomarker analysis.
Main Results:
- This study is designed to provide comprehensive data on AF management in China.
- It will offer insights into treatment patterns and patient outcomes.
- Ischemic stroke events will be adjudicated by an independent committee.
Conclusions:
- CAFR will be the largest registry of Chinese AF patients, offering valuable real-world data.
- The study will inform contemporary AF management strategies.
- Long-term follow-up will enhance understanding of AF patient epidemiology.
Background:
Robust data on the contemporary management of atrial fibrillation (AF) patients in China are limited. Importantly current practice in AF management has changing dramatically in recent years. Data from a large registry study will enable us to evaluate the uptake and outcomes with different therapies in a large Chinese AF population.
Methods/Design:
The Chinese Atrial Fibrillation Registry study (CAFR) aims to enroll 20,000 consecutive atrial fibrillation (AF) patients from 32 tertiary and non-tertiary hospitals in Beijing, China, and follow up these patients every 6 months until 2020. Key data collected includes basic sociodemographic information, symptoms and signs, medical history, results of physical examination and laboratory test, details of treatments and personal insurance status. For patients who consent, 5 ml of blood sample will be stored at -80 °C for future analyses of biomarkers. At each 6 month follow up visit, data relating to clinical outcomes will be collected. Data from a randomly selected 10 % of patients will be internally validated with their raw source data. Ischemic stroke events will be adjudicated by an independent endpoint committee.
Discussion:
CAFR will be one of the largest registries of Asian AF patients (and the largest in Chinese AF patients), as well as providing the longest follow up. This study would provide a valuable opportunity for 'real world' clinical epidemiology with insights into the uptake (and outcomes) of contemporary AF management.
Trial Registration:
Chinese Clinical Trial Registry ChiCTR-OCH-13003729 . Registered 22 October 2013.
